Microcap Ledger

Tickers · $CPHI

China Pharma Holdings, Inc. $CPHI

By Microcap Ledger desk · CIK 0001106644

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
NYSE American
Sector
Pharmaceutical Preparations
Headquarters
Hainan Province, China
Fiscal year end
December 31
Shares outstanding
43,022,002 [10-Q 2026-08-14]
as of 2026-08-11

Sources: [10-K 2026-04-01]

What the company doesAI summary of filing

China Pharma Holdings Inc. is a Nevada holding company that develops, manufactures, and markets pharmaceutical products in the People's Republic of China through its wholly owned subsidiary Helpson. The company produces 19 pharmaceutical products in various forms (tablets, capsules, injectables) targeting high-incidence and high-mortality diseases, including cardiovascular, central nervous system, infectious, and digestive conditions, along with comprehensive healthcare and protective products. All products are approved by China's National Medical Products Administration and sold primarily on a prescription basis to hospitals and pharmacies through a provincial and municipal distribution network. The company is revenue-generating, with total revenues of approximately $4.1 million in 2025 across its three pharmaceutical product categories. [10-K 2026-04-01]

Segments: CNS and Cerebral-Cardiovascular Diseases, Anti-Infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare and Protective Products

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$1.93M−$2.60M −$88.1K$304.9K[10-Q 2026-08-14]
FY ended Dec 2025$4.14M−$3.19M $148.3K$345.1K[10-K 2026-04-01]
FY ended Dec 2024$4.53M−$4.74M −$406.1K$626.9K[10-K 2026-04-01]
Quarterly cash burn
−$44.1K
Cash runway Estimate
~20.8 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-1219,253,363[10-Q 2024-11-13]
2025-03-2432,619,109[10-K 2025-03-31]
2025-05-143,262,002[10-Q 2025-05-14]
2025-08-073,262,002[10-Q 2025-08-14]
2025-11-105,022,002[10-Q 2025-11-12]
2026-03-2540,522,002[10-K 2026-04-01]
2026-05-1140,522,002[10-Q 2026-05-15]
2026-08-1143,022,002[10-Q 2026-08-14]
Shelf registration
S-3 filed 2024-01-12; declared effective 2024-02-14 [S-3 2024-01-12]

Listing status

Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.

More on deficiency notices and uplistings: Listing status desk.

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.